Clinical Trial Update: SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating TGF-beta inhibition combined with stereotactic ablative radiotherapy for early stage non-small cell lung cancer has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TGF-beta inhibitor (investigational; not specified in snippet)
• stereotactic ablative radiotherapy

Snippet

Sponsor: Maximilian Diehn | Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-27